Sunday, 30 October, 2011 08:00
Written by Danie Roy
Danie Roy
After writing my “just the facts” post on the ECJ ruling against patenting of certain stem cell research, I did some more leisurely reading on the topic. It seems that the reactions have two tones: “IT IS THE END OF THE WORLD” and “ABOUT TIME.” Oddly enough, both reactions appear to be based on the same misconceptions of the ruling. Of course, after reading all the extreme reactions, I realized I had to discuss the topic a little more.
First, I’d like to address the misconception with the reality a little more emphatically: embryonic stem cell research is not banned in the EU. The ruling stated that such research cannot be patented if it destroys the embryo.

Vodka might work, but, again, don't try it at home.
I have to emphasize embryonic because, on the extreme side, some believe that all stem cell research has been banned. Not so. There was absolutely no ruling regarding adult stem cell and induced pluripotent stem cell (iPSC) research. And, again, the research was not banned, just ruled to be unpatentable. Some things just aren’t patentable, like potatoes. If, however, I find a particularly special use for potatoes, say, as a jewelry cleaner (please don’t try this at home, I’m not going to be responsible for your tubered jewelry), I could certainly get a patent on a method of using potatoes to clean jewelry. So, the question is, does the same principle work here?
The answer is… maybe. So far the patents in question appear to have been worded in such a way as to attempt to patent the stem cells themselves and their extraction. We’ll see how things shape up as registered practitioners try to draft around this ruling.

This is what it is about.
So, why the extreme reactions? Well, many are equating “not patentable” with “not profitable.” The logic here is, if the invention isn’t patented, the market isn’t cornered. If the market isn’t cornered, the invention won’t make lots of money. If the invention won’t make lots of money, why invest? If nobody invests, why do research?
While this line of thought makes some sense, it’s only partly right. See, some researchers are actually getting a little excited about the ruling, because this means the cost of research goes down: if there aren’t any patents on production, getting the tools to make therapies is cheaper and easier. And if the therapies themselves can be patented (we don’t know yet), then this ruling may be the best thing to happen for people hoping and waiting for stem cell therapies. Keep in mind that this does not apply to adult stem cell research and iPSC research, which are believed to have a much lower chance of immune system rejection when applied therapeutically. Stem cells are part of a very young science, though, so only time will tell.
Keep in mind, even though this kind of research isn’t patentable in the EU, it IS patentable in other countries, such as the US and China. The research is profitable SOMEWHERE, so there will be backers, and some of them will still be European. In short:
